Adamas Pharmaceuticals Inc (ADMS) CEO Gregory T. Went Sells 4,541 Shares

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) CEO Gregory T. Went sold 4,541 shares of the company’s stock in a transaction dated Wednesday, March 21st. The stock was sold at an average price of $25.75, for a total value of $116,930.75. Following the sale, the chief executive officer now owns 182,610 shares in the company, valued at approximately $4,702,207.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

ADMS stock opened at $23.82 on Friday. Adamas Pharmaceuticals Inc has a 1-year low of $13.50 and a 1-year high of $44.00. The company has a current ratio of 10.79, a quick ratio of 10.69 and a debt-to-equity ratio of 1.55.

How to Become a New Pot Stock Millionaire

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.84 million. During the same quarter in the prior year, the firm posted ($0.68) EPS. The business’s revenue was up 1435.1% on a year-over-year basis. equities analysts anticipate that Adamas Pharmaceuticals Inc will post -6.16 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADMS. SG Americas Securities LLC purchased a new position in shares of Adamas Pharmaceuticals in the 3rd quarter valued at about $110,000. Quantbot Technologies LP purchased a new position in shares of Adamas Pharmaceuticals in the 3rd quarter valued at about $119,000. Sei Investments Co. increased its holdings in shares of Adamas Pharmaceuticals by 1,105.0% in the 3rd quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock valued at $185,000 after acquiring an additional 8,033 shares during the last quarter. Granite Springs Asset Management LLC purchased a new position in shares of Adamas Pharmaceuticals in the 4th quarter valued at about $207,000. Finally, FNY Partners Fund LP purchased a new position in shares of Adamas Pharmaceuticals in the 3rd quarter valued at about $231,000. Institutional investors and hedge funds own 77.25% of the company’s stock.

Several equities research analysts have weighed in on the company. Mizuho restated a “buy” rating and set a $48.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, January 23rd. BidaskClub upgraded Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 25th. ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Wednesday, January 3rd. Finally, Cowen set a $55.00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $45.14.

WARNING: “Adamas Pharmaceuticals Inc (ADMS) CEO Gregory T. Went Sells 4,541 Shares” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3296218/adamas-pharmaceuticals-inc-adms-ceo-gregory-t-went-sells-4541-shares.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Anticipate Axon  Will Announce Quarterly Sales of $91.82 Million
Brokerages Anticipate Axon Will Announce Quarterly Sales of $91.82 Million
John Robert Kneisel Sells 2,991 Shares of Simulations Plus  Stock
John Robert Kneisel Sells 2,991 Shares of Simulations Plus Stock
Twilio  General Counsel Sells $147,882.00 in Stock
Twilio General Counsel Sells $147,882.00 in Stock
Insider Selling: ICF  Insider Sells 2,957 Shares of Stock
Insider Selling: ICF Insider Sells 2,957 Shares of Stock
Wintrust Financial Co.  Insider Edward J. Wehmer Sells 3,300 Shares
Wintrust Financial Co. Insider Edward J. Wehmer Sells 3,300 Shares
MidSouth Bancorp  Position Boosted by Millennium Management LLC
MidSouth Bancorp Position Boosted by Millennium Management LLC


© 2006-2018 Ticker Report. Google+.